natgillin/translations-raw huggingface dataset:
The process of claim 3, wherein P is selected from the group consisting of THP or SiR1R2R3, wherein R1, R2 and R3 are independently selected from the group consisting of H, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, alkylaryl, heterocyclic, and heteroaryl. 
ciklizacije Spoja 18 u prvom otapalu, na povišenoj temperaturi [image] gdje R7 se bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine kako bi se dobilo prvu smjesu, koju čine a- i B-exo-izomer Spoja 17A:
Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. 
Masti i kreme mogu, na primjer, biti formulirani sa vodenom ili uljnom bazom sa dodatkom prikladnog sredstva za zgušnjavanje i/ili geliranje.
The dental post according to claim 1, wherein X-ray absorbing material is embedded in said post. The dental post according to claim 14, wherein said X-ray absorbing material comprises a mineral filler comprising a chemical compound with an element of an atomic number of at least 37. 
Zubni most u skladu s patentnim zahtjevom 3, naznačen time što navedeni materijal koji apsorbira rendgensko zračenje sadrži mineralno punilo koje sadrži kemijski spoj s elementom s atomskim brojem od najmanje 37, poželjnije od najmanje 57, osobito iterbijem.
The host cell according to claim 12 wherein the cell is mammalian. 
Stanica domaćin u skladu s patentnim zahtjevom 12, naznačena time što je stanica sisavačka.
m is an integer ranging from 0 to 5; 
m je cijeli broj u rasponu od 0 do 5;
The front wall and/or the side walls have a cut-out in the extrusion ridge. 
Prednji zid iili bočni zidovi imaju otvor u prijeloma u obliku izbočenja.
A compound of formula I: wherein A is NH2; and B is H; or pharmaceutically acceptable salt or hydrate thereof, for use in the inhibition of a RNA viral polymerase selected from the group consisting of orthmyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae viral polymerases. 
Spoj za uporabu sukladno zahtjevu 1, pri čemu virusna infekcija sadrži virus odabran iz skupine koja se sastoji od virusa iz obitelji orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae.
Heteromolecular metal complexes (chelates) disclosed in claim 1, wherein molecule A is a humic acid extracted from one or several sedimentary organic materials (leonardite, lignite or peat) or/and fresh vegetable compost. 
Heteromolekularni metalni kompleksi (kelati) otkriveni u zahtjevima 1 do 6, naznačeni time što je molekula A huminska kiselina izlučena iz jednog ili više sedimentarnih organskih materijala (leonardita, lignita ili treseta) ili/i svježeg povrtnog komposta.
The compound of Claim 28, wherein Y1 is an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted thiophenyl, [1,2,3]thiadiazolyl, an optionally substituted isoxazolyl, 1H-pyrazolyl, quinolinyl, imidazolyl, or 2,3-dihydrobenzo[1,4]dioxine. 
Spoj prema zahtjevu 28, naznačen time da Y, je opcijski supstituiran feril, opcijski supstituiran piridil, opcijski supstituiran tiofenil, [1,2,3 [tiadiazolil, opcijski supstituiran izoksazolil, 1H-pirazolil, kvinolinil, imidazolil, ili 2,3-dihidrobenzo[1,4]dioksin. .
Compound of Formula I for use in the treatment, prevention or amelioration of disorders in an animal, which disorder is treated, prevented or ameliorated by activation of an opioid receptor wherein the disorder is selected from the group consisting of pain, wherein the compound of Formula I is: wherein A is aryl, or heteroaryl; is: 
Spoj sa formulom I for naznačen time da je za uporabu kod liječenja, sprečavanja ili ublažavanja poremećaja kod životinje, koji poremećaj se liječi, sprečava ili ublažava pomoću aktivacije opioidnog receptora pri čemu poremećaj je odabran iz skupine koja sadrži bol, pri čemu spoj sa formulom I je: [image] pri čemu A je aril ili heteroaril;
For example, as shown in Figure 22, 2'-O-TBDMS-9,10-a,a-OH, 9 desoxo, 10 deacetyl paclitaxel of Formula 8 (where R1=R2=Ph; P1= TBDMS in generalized formula H of Scheme 4) may be mono-acylated on the 7-hydroxyl as Formula 12 (corresponding to generalized formula J of Scheme 4), bis-acylated on the 7,10-hydroxyls as Formula 13 (corresponding to generalized formula J' of Scheme 4), and/or tris-acylated on the 7,9,10-hydroxyls as Formula 14 (corresponding to generalized formula J" of Scheme 4). 
Na primjer, kao što je prikazano na slici 22, 2'-O-TBDMS-9,10-a,a-OH, 9-dezokso, 10 deacetil paklitaksela formule 8 (gdje R;=R,=Ph; P,=TBDMS u općoj formuli H iz sheme 4) može biti mono-aciliran na 7-hidroksilu kao formula 12 (što odgovara općoj formuli J iz sheme 4), bi-aciliran na 7,10-hidroksilnim skupinama kao formula 13 (što odgovara općoj formuli J' iz sheme 4), i/ili tri-aciliran na 7,9,10-hidroksilnim skupinama kao formula 14 (što odgovara općoj formuli J" iz sheme 4).
The method of claim 13, wherein the peptide has an amino acid sequence comprising or consisting of SEQ ID NO:69. 
Himerni peptid sukladno zahtjevu 1, naznačen time što se sastoji od SEQ ID NO:69.
An advantageous form of the above embodiment of the invention is where the avermectin or milbemycin is selected from the group consisting of eprinomectin, ivermectin, and moxidectin. 
Tekuća imjektibilna formulacija s produljenim djelovanjem prema zahtjevu 1, naznačena time, da je prva bioaktivna tvar odabrana od eprinomektina, ivermektina i moksidektina.
initialisation of the system of encryption at first access by means of: 
inicijalizacije sustava enkripcije kod prvog pristupa putem:
Preferably, it produces a gentle, consistent mist under the pressure and input conditions of system 10. 
Poželjno je da proizvodi blagu, konzistentnu maglu pod tlakom i ulaznim uvjetima sustava 10.
The method according to any one of claims 1 to 4 wherein the fusion protein is produced by expressing the fusion protein in a mammalian host cell. 
Heterologni fuzijski protein u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je namijenjen upotrebi u liječenju dijabetes melitusa neovisnog o inzulinu.
A compound of formula (IV): or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: 
Spoj s formulom (I): [image] ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer, naznačen time da: X je C=O ili CH2;
The compound of claim 1 wherein R4 is phenyl substituted with one to three R41 substituents independently selected from the group consisting of (C1-3)alkyl, (C1-3)alkoxy, phenyl(C1-3)alkoxy, hydroxy, C1-6alkylaminocarbonyl, and aminocarbonyl; provided that no more than one R41 substituent is aminocarbonyl, C1-6alkylaminocarbonyl, hydroxy, or a phenyl-containing substituent. 
Spoj prema zahtjevu 1 naznačen time da R" je fenil supstituiran sa jednim do tri R"' supstituenta nezavisno izabrana iz skupine koju čine (Crs)alkil, (Crg)alkoksi, feni(C,.)alkoksi, hidroksi, C,salkilaminokarbonil i aminokarbonil; uz uvjet da ne više od jedan R"' supstituent je aminokarbonil, C, galkilaminokarbonil, hidroksi ili supstituent koji sadrži fenil.
The sprectra were normalised on the highest absorption in the 250-300 nm area (figures). 
Spektri su normalizirani na najvišu apsorpciju u području od 250-300 nm (slike).
a dip-moulding stage (12, 13) for coating and curing on said formers said gloves; 
stanicu (12, 13) za oblikovanje uranjanjem za oblaganje i stvrdnjavanje navedenih rukavica na navedenim kalupima;
The anti-PD-1 antibody or the antigen-binding fragment thereof according to claim 9, wherein the antibody or the antigen-binding fragment thereof is a chimeric antibody or a fragment thereof. The anti-PD-1 antibody or the antigen-binding fragment thereof according to claim 11, wherein the chimeric antibody comprises a light chain variable region having the amino acid sequence of SEQ ID NO: 10. The anti-PD-1 antibody or the antigen-binding fragment thereof according to claim 11, wherein the chimeric antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO: 9. 
3, SEKID BR: 4 i SEK ID BR: 5, sukladno opisanom redoslijedu PD-1 protutijelo ili njegov fragment koji se veže na antigen sukladno patentnom zahtjevu 1, pri čemu je to protutijelo ili njegov fragment koji se veže na antigen kimerno protutijelo. PD-1 protutijelo ili njegov fragment koji se vezuje na antigen sukladno patentnom zahtjevu 2, pri čemu promjenljiva regija lakog lanca obuhvaća sekvencu amino kiseline prikazane u SEK ID BR:10 i promjenljiva regija teškog lanca obuhvaća sekvencu amino kiseline prikazane u SEK ID BR:9.
an antibody heavy chain variable domain as defined in Claim 3. The antibody or antigen binding fragment thereof of Claim 4 comprising a light chain and a heavy chain, wherein: 
Antitijelo ili antigen-vežući fragment istog iz Zahtjeva 4, naznačeno time, što sadrži laki lanac i teški lanac, pri čemu:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
A pharmaceutical composition comprising a digestive enzyme powder blend comprising a digestive enzyme, and a carrier wherein: 
Kompozicija koja sadrži najmanje jedan digestivni enzim i najmanje jedan nosač, naznačena time što je:
at least one group of circumferentially spaced inner air ducts is formed in said rotor at a radial position close to said drive shaft. The induction motor according to claim 8, wherein: 
- u navedenom rotoru (30) je u radijalnom položaju blizu navedenog pogonskog vratila (31) načinjena najmanje jedna skupina unutarnjih vodova za zrak (36a), razmještenih po obodu.
The therapeutic and/or prophylactic agent for use in treating a tumor according to claim 1, wherein the tumor is selected from the group consisting of acute myelogenous leukemia, chronic myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, brain tumor, neuroblastoma, glioma, thyroid cancer, myelodysplastic syndrome, head and neck cancer, esophageal cancer, gastric cancer, colorectal cancer, breast cancer, ovarian cancer, lung cancer, pancreatic cancer, liver cancer, gallbladder cancer, skin cancer, malignant melanoma, kidney cancer, renal pelvic and ureteral cancer, bladder cancer, uterine cancer, testicular cancer, prostate cancer, and tumors metastasized from these tumors. 
Terapijsko 1/ili profilaktičko sredstvo namijenjeno upotrebi u liječenju tumora u skladu s patentnim zahtjevom 1, naznačeno time što se tumor bira iz skupine koju čine akutna mijelogena leukemija, kronična mijelogena leukemija, akutna limfocitna leukemija, kronična limfocitna leukemija, Hodgkinov limfom, nehodgkinovski limfom, tumor na mozgu, neuroblastom, gliom, rak štitnjače, mijelodisplastični sindrom, rak glave i vrata, rak jednjaka, rak želuca, kolorektalni rak, rak dojke, rak jajnika, rak pluća, rak gušterače, rak jetre, rak žučnog mjehura, rak kože, zloćudni melanom, rak bubrega, rak nakapnice i mokraćovoda, rak mokraćnog mjehura, rak maternice, rak testisa, rak prostate, te tumori metastazirali iz tih tumora.
In another embodiment the infectious disease is caused by a virus. 
Spoj ili terapijski prihvatljiva sol za primjenu prema patentnom zahtjevu 9 gdje infektivna bolest je uzrokovana virusom.
A pharmaceutical composition according to claim 8, wherein the amount of the gelling agent is from 1 to 30% (w/w), per weight of the composition. 
Farmaceutski pripravak u skladu s patentnim zahljevom 8, naznačen time, da je udjel sredstva za geliranje u rasponu od 1 do 30 % (w/w) u odnosu na ukupnu masu pripravka.
Two further lots were similarly prepared on a larger scale (0.4 mmol and 11 mmol, respectively), using a 2.3-2.5-fold excess of peracetic acid, and altering solvent ratios and quantities slightly. 
Dva sljedeća lota pripremljena su slično na duljoj skali (0.4 mmol i 11 mmol), upotrebom 2.3-2.5 više peroctenc kiselinc, i mijenjajući odnose otapala i količine postupno.
Low molecular alcohols or ethers are preferred, such as methanol, ethanol, propanol, isopropanol and/or diethylether. 
Prednost se daje alkoholima ili eterima niske molekulske mase, kao što su metanol, etanol, propanol, izopropanol i/ili dietil eter.
a pharmaceutical product comprising such an agent of the invention in inhalable form in association with an inhalation device; and 
(c) farmaceutski proizvod koji sadrži takovo sredstvo izuma u obliku koji se može inhalirati zajedno s napravom za inhalaciju; i
Ring B is a benzene ring which may optionally be substituted by a substituent selected from a halogen atom, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, and a halo-lower alkoxy group. 
heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom, halogen-C1-6 alkilnom skupinom, C1-6 alkoksi skupinom ili halogen-C1-6 alkoksi skupinom; i RC je atom vodika.
The left carotid artery was isolated and a Parafilm M sheet (7 x 20 mm, American National Can) was placed under it. 
Izolirana je lijeva karotidna arterija 1 ispod nje je stavljena pločica Parafilma M (7 x 20 mm, American National Can).
The isolated cell of claim 9 or claim 10, further comprising a nucleotide sequence encoding a human or humanized B2 microglobulin polypeptide operably linked to endogenous non-human B2 microglobulin regulatory elements. 
Izolirana stanica prema zahtjevu 9 ili zahtjevu 10, naznačena time, da nadalje obuhvaća nukleotidnu sekvencu koja kodira ljudski ili humanizirani polipeptid B2-mikroglobulina koji je operativno povezan s endogenim neljudskim regulacijskim elementima B2-mikroglobulina.
R2a is hydrogen, C1-6alkyl, C3-8cycloalkyl, C5-8cycloalkenyl, phenyl or 3-8 membered heterocyclic group containing at least one of O, S and N, said C1-6alkyl, C3-8cycloalkyl, C5-8cycloalkenyl, phenyl and 3-8 membered heterocyclic group can be optionally substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from the group consisting of halogen, cyano, hydroxyl, carboxyl, amino, C1-6alkyl and haloC1-6alkyl; 
R* je vodik, C,galkil, Ca_gcikloalkil, Cs gcikloalkenil, fenil ili 3-8 člana heterociklična skupina koja sadrži barem jedan od O, S i N, spomenuti C;galkil, Ca gcikloalkil, Cs .gcikloalkenil, fenil i 3-8 člana heterociklična skupina mogu izborno biti supstituirani s 1, 2, 3, 4, 5 ili 6 supstituenata nezavisno odabranih iz skupine koja se sastoji od halogena, cijano, hidroksila, karboksila, amino, Ci .salkila i haloC, salkila;
A pharmaceutical composition comprising the compound as described in claim 18 or a pharmaceutically acceptable salt, or prodrug thereof and at least one pharmaceutically acceptable carrier. 
Spoj ili farmaceutski prihvatljiva sol, kako je opisano u patentnom zahtjevu 1, za upotrebu pri medicinskoj terapiji. Farmaceutski sastav koji se sastoji iz spoja iz patentnog zahtjeva 2 i inhibitora NS5B polimeraze.
iii) the second Fab fragment, the third Fab fragment and the Fc domain are part of an immunoglobulin molecule and the immunoglobulin molecule is an IgG1 or IgG4 subclass immunoglobulin molecule; and/or iv) the second Fab fragment, the third Fab fragment and the Fc domain are part of an immunoglobulin molecule and the immunoglobulin molecule is a human immunoglobulin molecule. 
1) drugi Fab fragment, treći Fab fragment i Fc domena su dio molekule imunoglobulina, a molekula imunoglobulina je molekula imunoglobulina razreda IgG; ili) drugi Fab fragment, treći Fab fragment i Fc domena su dio molekule imunoglobulina, a molekula imunoglobulina je molekula imunoglobulina podrazreda IgG1 ili IeG4; 1/ili iv) drugi Fab fragment, treći Fab fragment i Fc domena su dio molekule imunoglobulina, a molekula imunoglobulina je molekula humanog imunoglobulina.
An antibody, or antigen-binding fragment thereof, according to claim 5, wherein said influenza infection is caused by an influenza virus that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak. 
Antitijelo, ili njegov dio koji veže antigen, prema zahtjevu 5, naznačeni time da je navedena infekcija influence uzrokovana sa virusom influence koji se povezuje sa izbijanjem pandemije, ili ima potencijal da se poveže sa izbijanjem pandemije.
A compound or salt of any one of claims 1 to 4 and 6 to 8, an amorphous form of claim 9, a crystalline Form B of claim 10, or a pharmaceutical composition of claim 12 for use in a method of treating or lessening the severity in a subject of chronic pain, gut pain, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, postsurgical pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough, or cardiac arrhythmia. 
Spoj ili sol prema bilo kojem od patentnih zahtjeva od 1 do 41 od 6 do $, amorfni oblik prema patentnom zahtjevu 9, kristalni Oblik B prema patentnom zahtjevu 10 ili farmaceutski pripravak prema patentnom zahtjevu 12 naznačen time što je za upotrebu u postupku liječenja ili smanjenja intenziteta boli kod subjekta s kroničnom boli, crijevnom boli, neuropatskom boli, mišićno-skeletnom boli, akutnom boli, upalnom boli, boli zbog raka, idiopatskom boli, boli nakon kirurške intervencije, visceralnom boli, boli zbog multiple skleroze, Charcot-MarieTooth sindroma, inkontinencije, patološkog kašlja ili srčane aritmije.
The aqueous pharmaceutical suspension according to claim 7, wherein the buffering uses a buffer system comprising, by weight/volume (g/100 mL), about 0.75% to about 1.00% of sodium phosphate monobasic monohydrate, and about 0.60% to about 1.25% of sodium phosphate dibasic heptahydrate. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što puferiranje se vrši puferskim sustavom koji sadrži, težinskićvolumno (g/100 ml), otprilike 0,75 % do otprilike 1,00 % jednobaznog natrijevog fosfata monohidrata, te otprilike 0,60 % do otprilike 1,25 % dvobaznog natrijevog fosfata heptahidrata,
Detection system as claimed in any of the claims 14-20, characterized in that the transmitting and receiving device is adapted to calculate from the received reflections the speed and the travel direction of the passing vehicle. 
Sustav detekcije prema bilo kojem od zahtjeva 10 do 12, naznačen time što je uređaj za odašiljanje i primanje (4) prilagođen za izračunavanje iz primljenih refleksija brzine i smjera vožnje prolazećeg vozila (V).
Esophageal candidiasis, for example, can be extraordinarily uncomfortable, making swallowing difficult and eating painful or, in some cases, impossible. 
Kandidijaza jednjaka, na primjer, može biti izuzetno neugodna, čineći gutanje i jedenje bolnim ili, u nekim slučajevima, nemogućim.
The method of claim 1, wherein the quantized coefficients of each subset are scanned in a reverse direction according to a scan pattern determined by the intra prediction mode. 
Uređaj prema zahtjevu 1, naznačen time da entropijski koder (130) kodira položaje ne-nultih koeficijenata i informacije za identifikaciju ne-nultih koeficijenata svakog pod-bloka.
is selected from His and X; 
X20 je odabran od His i X;
A cement according to claim 1, wherein the carbonate material and the clay material have been calcined in a mixture at a temperature of less than 800°C, and preferably less than 700 °C. A cement according to any claims 1-2, wherein the clay material has been transformed to a calcium aluminosilicate glass. A cement according to any claims 1-3, wherein the clay material is calcined clay. 
Cement prema zahtjevu 1, naznačen time što je kalcinirani glineni materijal kalcinirana glina proizvedena na temperaturi od između 500ºC i 750ºC. Cement prema bilo kojem od prethodnih zahtjeva, naznačen time što toplinski obrađeni glineni materijal čini najmanje 7 % m/m i karbonatni materijal čini najmanje 8 % m/m cementa.
A compound according to claim 11, or a pharmaceutically acceptable salt thereof, wherein R3 is methyl and the stereocentre produced has the (R)-configuration. 
Spoj u skladu s patentnim zahtjevom 11 ili njegova farmaceutski prihvatljiva sol, naznačen time, da R? je metil, a nastali stereocentar ima (R)-konfiguraciju.
at least one lubricant in a total amount of less than 0.1% to 2% by weight based on the total weight of the tablet; and optionally, a coating. 
najmanje jedan lubrikant u ukupnoj količini od manje od 0,1 do dva masena postotka na osnovi ukupne mase tablete, gdje taj lubrikant je magnezijev stearat; i
The filtration device of claim 3, wherein the rigidified fabric is made of woven threads of glass fibers, silica fibers or a mixture thereof. 
Tkanina u skladu s patentnim zahtjevom 4 izrađena je od tkanih niti od staklenih vlakana, silicijskih vlakana ili njihove smjese.
The mouse of claim 6, wherein the endogenous λ (lambda) light chain allele comprises four unrearranged human Jλ gene segments. 
Miš prema zahtjevu 1, naznačen time, što se alel endogenog lakog 2 (lambda) lanca sastoji od četiri nepreuređena segmenta gena JA.
The crystalline R(+)-N-propargyl-1-aminoindan of claim 1 characterized by a powder X-ray diffraction pattern having peaks at 8.5, 12.6, 16.1, 16.9, 20.3, 20.9, 25.4, 26.4, and 28.3 in degrees two theta ±0.2. 
Kristalni R(+)-N-propargil-1-aminoindan prema patentnom zahtjevu 1, naznačen time, da slika rendgenske difrakcije praha ima pikove na 8,5, 12,6, 16,1, 16,9, 20,3, 20,9, 25,4, 26,4 i 28,3 u stupnjevima dva-teta ±0,2.
The method of claim 1 or 2 wherein the ion exchange membrane has a pore size of 0.1 to 100 µm. 
Postupak prema patentnom zahtjevu 1 ili 2, naznačen time, da membrana ionske izmjene ima veličinu pora od 0,1 do 100 um.
Copper effectiveness against wood decay fungi makes it important constituent of wood preservatives for almost 200 years. 
Djelotvornost bakra protiv gljivičnog propadanja drva ga čini važnim sastavnim dijelom drvnih konzervansa već skoro 200 godina.
The reaction mixture was stirred for 15 minutes at room temperature. 
Reakcijska smjesa se miješa 15 minuta na sobnoj temperaturi.
3-Amino-5,6-bis-trifluoromethyl-pyridine-2-carboxylic acid ((R)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide of formula or a pharmaceutically acceptable salt thereof. A pharmaceutical composition for use in the treatment of chronic obstructive pulmonary disease, comprising: 
Uporaba spoja, ili njegove farmaceutski prihvatljive soli, prema zahtjevu 13, naznačena time, da spoj je 3-amino-5,6-bis-trifluorometil-piridin-2-karboksilna kiselina-((R)-3,3,3-trifluoro-2-hidroksi-2-metil-propil)-amid.
The resulting crude residue is loaded on a pre-packed Isolute™ silica column and eluted with iso-hexane:ethyl acetate (1:8) to yield the titled compound as a white powder. 
Dobiveni sirov ostatak se stavi na predpakirani Isolute "" stupac silika gela i ispere se s izo-heksan:etil acetatom (1:8), čime se dobije naslovni spoj kao bijeli prah.